Comparative Pharmacology
Head-to-head clinical analysis: OMEPRAZOLE MAGNESIUM versus PRILOSEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMEPRAZOLE MAGNESIUM versus PRILOSEC.
OMEPRAZOLE MAGNESIUM vs PRILOSEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omeprazole magnesium is a proton pump inhibitor (PPI) that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing gastric acid secretion.
Omeprazole is a proton pump inhibitor that irreversibly inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, thereby blocking the final step of gastric acid secretion.
20 mg orally once daily for 4-8 weeks; for erosive esophagitis 20-40 mg orally once daily for 4-8 weeks; maintenance: 10-20 mg orally once daily; for Helicobacter pylori eradication: 20 mg orally twice daily for 10-14 days in combination with antibiotics.
20 mg orally once daily before a meal for 4-8 weeks for GERD; for duodenal ulcer, 20 mg once daily for 4 weeks; for Zollinger-Ellison syndrome, initial dose 60 mg orally once daily, titrate up to 120 mg three times daily as needed.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour (fast metabolizers); 2-3 hours (slow metabolizers); clinical context: prolonged in hepatic impairment, no significant accumulation with once-daily dosing due to irreversible inhibition of H+/K+-ATPase.
Terminal elimination half-life: 0.5–1 hour in healthy subjects (elimination phase); clinical context: acid suppression persists >24 hours due to irreversible binding to parietal cell H+/K+-ATPase.
Renal: 77% as metabolites; biliary/fecal: 16.7% as metabolites; active drug not excreted unchanged.
Renal: ~77% as metabolites; fecal: ~20% as metabolites (biliary/fecal). Unchanged drug negligible.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor